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ABBREVIATIONS 
Aβ, β-amyloid 
AD, Alzheimer's disease 
AUC, area under the curve 
BBB, blood-brain barrier 
CSF, cerebrospinal fluid 
E-net, Elastic net 
MCI, mild cognitive impairment 
NDC, non-demented controls 
p-tau181,  tau phosphorylated at threonine 181 
RC, regression coefficient 
Rs, Spearman Rank correlation coefficient 
t-tau, total tau 
CLSI, Clinical Laboratory Standards Institute 
 
Abbreviations of all measured proteins are listed separately in Supplemental Table S2. 
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SUMMARY 1 
The study of chronic brain diseases including Alzheimer's disease in patients is typically limited to 2 
brain imaging or psychometric testing. Given the epidemic rise and insufficient knowledge about 3 
pathological pathways in sporadic Alzheimer's disease, new tools are required to identify the 4 
molecular changes underlying this disease. We hypothesize that levels of specific secreted cellular 5 
signaling proteins in cerebrospinal fluid or plasma correlate with pathological changes in the AD 6 
brain and can thus be used to discover signaling pathways altered in the disease. Here we 7 
measured 91 proteins of this subset of this cellular communication proteome in plasma or 8 
cerebrospinal fluid in patients with Alzheimer's disease and cognitively normal controls to 9 
mathematically model disease-specific molecular traits. We found small numbers of signaling 10 
proteins that were able to model key pathological markers of Alzheimer's disease, including levels 11 
of cerebrospinal fluid β-amyloid and tau, and classify disease in independent samples. Several of 12 
these factors had previously been implicated in Alzheimer's disease supporting the validity of our 13 
approach. Our study also points to proteins which were previously unknown to be associated with 14 
Alzheimer's disease thereby implicating novel signaling pathways in this disorder. 15 
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INTRODUCTION 1 
The brain regulates key biological processes throughout the organism by releasing 2 
molecules into the blood and cerebrospinal fluid (CSF), and systemic factors in turn can induce 3 
cognitive and behavioral changes in animals and humans (1, 2). Thus, brain and periphery are 4 
interconnected not only on a cellular level but also in a complex molecular network of soluble 5 
communication factors.  6 
Alzheimer’s disease (AD) is the most common form of dementia affecting an estimated 5.4 7 
million individuals in the US (3). The cause of AD is not known but genetic and pathological studies 8 
point to a key role for cerebral β-amyloid (Aβ) peptide and hyperphosphorylated tau in the disease. 9 
Levels of soluble Aβ42 in CSF decrease in AD in parallel to its deposition into amyloid plaques in 10 
the brain parenchyma, whereas tau increases as the disease progresses making these proteins 11 
good biomarkers of AD (4-6). Moreover, ratios between the concentrations of tau phosphorylated 12 
at threonine 181 (p-tau181) and total tau (t-tau) or Aβ42 are predictive of future development of AD 13 
in patients with mild cognitive impairment (MCI) (7-9) and cognitive decline (10-12) or brain atrophy 14 
in non-demented older adults (13). Despite the usefulness of these CSF markers in the diagnosis 15 
of AD patients (4, 5), they provide little information on biological mechanisms involved in this 16 
disorder. 17 
Some members of the molecular network which include cytokines, chemokines, or growth 18 
factors have been reported to have different expression levels in patients with neurological 19 
diseases compared to those found in healthy controls [reviewed in (14)]. We and others have 20 
measured in plasma or CSF from AD patients and controls large numbers of communication 21 
factors, which we collectively called the communicome, and by statistically comparing levels in AD 22 
patients versus levels in controls we identified small groups of factors that could form a signature 23 
for the disease (15-19). Together, these findings point to e.g. abnormal transcriptional regulation of 24 
peripheral leukocytes (20, 21) or neuroinflammatory pathways in AD (22). Technical problems and 25 
small sample sizes, however, have made it difficult to identify proteins, which are predictive of AD 26 
across various centers and studies (18) and the two-class analysis approach (AD patients versus a 27 
control group) is appealing for finding differences but provides little insight into the role of these 28 
markers in AD.  29 
Here we propose an alternative analytical approach in which levels of communication factors 30 
in CSF and plasma are used to mathematically model levels of Aβ42 and tau. We do this based on 31 
the hypothesis that the systemic network of the extracellular signaling proteome is linked with the 32 
levels of CSF markers of AD pathology and indicators of disease progression. The findings could 33 
help in identifying proteins and biological pathways hitherto unknown to be involved in AD. 34 
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EXPERIMENTAL PROCEDURES 1 
Subjects and APOE genotyping. AD patients and healthy non-demented controls (NDC) (Table 2 
S1) were recruited for multicentre studies that aim to identify molecular biomarkers for AD in blood 3 
and CSF. Subjects were chosen based on standardized inclusion and exclusion criteria (see 4 
Supplemental Methods). Written informed consent was obtained from all subjects, or assent from 5 
subjects and consent from caregivers in the case of subjects with significant impaired decisional 6 
capacity, in accordance with institutional ethics committee review boards at each participating 7 
institution. APOE genotyping was performed by the restriction digest method (23). 8 
 9 
Collection of CSF and plasma. CSF and plasma samples were generated by standard 10 
procedures as described (19, 24). Briefly, for the majority of patients lumbar puncture and blood 11 
draw was conducted between 9am and 11am after an overnight fast. After blood draw into K2- 12 
EDTA-coated lavender top vacutainers, blood was kept on ice, spun at 1000g in a refrigerated 13 
centrifuge within one hour of draw, aliquoted, and frozen on dry ice. All samples were stored at – 14 
80ºC until use with no previous thaw cycle. 15 
 16 
Measurement of analytes in CSF and plasma. We measured CSF levels of Aβ42, t-tau, and p- 17 
tau181 by Luminex xMAP method (AlzBio3, Innogenetics, Ghent, Belgium) a bead-based sandwich 18 
immunoassay. Plasma samples were shipped from Seattle to Palo Alto where they were thawed 19 
and aliquoted. For the multi-analyte profiling plasma aliquots were sent to Rules-Based Medicine 20 
(RBM, Austin, Texas) and measured in two big batches of samples from NDC and AD patients. 21 
CSF was sent directly to RBM and analyzed in one experiment. All samples were analyzed blinded 22 
by robotic sample handlers in a bead-based multiplex sandwich immunoassay (Luminex bead 23 
analyzer), according to Clinical Laboratory Standards Institute (CLSI) guidelines and rigorous 24 
assessment of fundamental assay parameters (http://www.rulesbasedmedicine.com/quality- 25 
policy/data-quality/). Out of 90 analytes measured by RBM IFN-γ, IGF-1, IL-1α, and lipoprotein-a 26 
were not detectable in any of the CSF and plasma samples. Additional analytes were excluded if 27 
they were detectable in less than 10% of samples. This resulted in 73 detectable proteins in each, 28 
plasma and CSF, with 60 proteins overlapping between the two biological fluids (Table S2). 29 
Soares and colleagues reported a similar sensitivity of this platform (18). As a quality control we 30 
remeasured 35 plasma samples at RBM 17 months after the initial plasma measurements. 86% of 31 
the detectable analytes correlated between the two measurements with a Pearson correlation 32 
coefficient R ≥ 0.7 (52% R ≥ 0.9, 34% R = 0.7-0.9) and 14% with R < 0.7. Lower R-values were 33 
due to changes in assay settings in the second experiment, which rendered most values for these 34 
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analytes below least detectable dose or undetectable. Nevertheless, these data generated at two 1 
independent time points made us confident, that RBM produces highly reproducible data. Also, 2 
analytes with low correlation coefficient were deemed suitable for analysis because in the first 3 
experiment they were well above detection limit. Only data from the first experiment were 4 
subsequently used for the analysis. In addition, plasma levels of MCSF were quantified separately 5 
by Quantikine ELISA (R&D Systems, Minneapolis, USA) and were detectable in all plasma 6 
samples.  7 
 8 
Statistical analysis. Analysis was done in Prism 5 and R [http://www.r-project.org/, (25)]. The 9 
entire plasma sample set contained 78 AD patients and 118 NDC (Table S1) and we measured 10 
levels of tau, p-tau181, and Aβ42 in 72 AD patients and 112 controls. We standardized the values to 11 
z-scores by subtracting the mean and dividing by the standard deviation (26). Measurements 12 
below lowest detectable protein concentration were imputed conservatively with the lowest 13 
available value of an analyte. Values missing at random (e.g. analyte not measured due to 14 
insufficient amounts of sample) were imputed with 0 (which is the mean of the available 15 
observations) after standardization. The entire plasma set was randomly split into a training set (79 16 
NDC, 52 AD) and a test set (39 NDC, 26 AD), whereby we insisted on the same AD versus NDC 17 
frequency distribution in the training and test as in the entire dataset and that all subjects in the 18 
training set have measurements for Aβ42 and tau. The CSF sample set was analyzed without 19 
further splitting. For the CSF sample set and the plasma training set high-dimensional linear 20 
regression models for continuous endpoints were computed with an elastic net penalty 21 
[http://cran.r-project.org/web/packages/elasticnet/index.html, (27)] using the add-on package 22 
elasticnet. We used the standardized levels of t-tau, p-tau181, Aβ42, or the ratios of Aβ42/t-tau, or 23 
Aβ42/p-tau181, respectively, as the continuous response variables in the linear regression equation 24 
and the standardized values of CSF or plasma protein levels together with sex and risk factors for 25 
AD APOE genotype and age as the explanatory variables. The penalty parameter was chosen via 26 
10-fold cross validation minimizing prediction error. For fixed alpha, the regularization parameter 27 
lambda is varied from lambda_max, the smallest lambda such that all coefficients are estimated 28 
without constraint, down to a very small lambda_min; lambda = 0 renders the algorithm unstable 29 
(28). We use the built-in specification of lambdas that automatically chooses a suitable number of 30 
lambdas in the interval [lambda_min, lambda_max]. For alpha we used {0.01, 0.2, 0.4, 0.6, 0.8, 1}. 31 
Alpha = 1 specifies a pure Lasso penalty. For each response a separate model was calculated 32 
(Table I, Model C1-5 in CSF, P6-8 in plasma) and variables that fitted best into the corresponding 33 
model (selected predictors) are listed in order of decreasing association to the response variable 34 
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(absolute size of regression coefficient, RC). To test the diagnostic utility of the selected predictors 1 
in both the training and the test set, we used the selected predictors to model the binary endpoint 2 
AD versus NDC (based on clinical diagnosis) and calculated a ROC curve where the linear 3 
predictor from the logistic regression was the continuous variable. This was compared to the ROC 4 
curve that is based on models with t-tau, p-tau181p, Aβ42, and their ratios Aβ42/t-tau, and Aβ42/p- 5 
tau181p, respectively. Comparison of the logistic regression analyses was done via ROC with 95% 6 
Wald-type confidence intervals for AUC on logit-scale were computed using the approach of 7 
Hanley and McNeil (29, 30). To assess the risk associated with APOE genotype we computed an 8 
ordinary logistic regression model with dependent variable AD versus non-AD and explanatory 9 
variable APOE4 status (ε4 versus non-ε4). In addition to the odds ratio we report a 95% profile 10 
likelihood confidence interval.  11 
 12 
Connectivity network diagrams. First, we calculated the Spearman rank correlation coefficients 13 
(RS) between all analytes in separate correlation matrices for AD patients and NDC, respectively. 14 
Confidence intervals for RS between analytes in plasma and CSF were calculated using Fisher's z- 15 
transformation and t-quantiles. The RS is an indicator of connectivity of two analytes and RS ranges 16 
[0.4,1] and [–1,–0.4] were used to draw connectivity network diagrams for selected analytes. To 17 
quantify the strength of integration of an analyte in the connectivity network we calculated for each 18 
analyte an interaction score, which is the sum of the squared values of all RS in the range of [–1,1] 19 
between this analyte and all analytes in the connectivity diagram.  20 
 21 
 22 
RESULTS 23 
Two thirds of measured communication factors are detectable in CSF. 24 
We measured the concentrations of 91 secreted proteins in plasma from 78 AD patients and 118 25 
cognitively normal elderly NDCs; we also measured 90 proteins in CSF of 25 AD patients and 18 26 
NDC (Table S1 and S2). These proteins represent some of the best-studied cytokines, 27 
chemokines, growth factors, and acute phase response proteins and were selected based on 28 
availability in multiplex sandwich immunoassay. Seventy-four proteins were detectable in plasma 29 
and 73 in CSF, with 60 proteins overlapping between the two biological fluids. Protein 30 
concentrations were generally lower in CSF than in plasma (between 5- to 8000-fold) with a few 31 
interesting exceptions. β2-microglobulin, CD40, CCL11/eotaxin, tissue inhibitor of 32 
metalloproteinase (TIMP)-1, or tissue factor (TF) were measured at similar concentrations in both 33 
fluids and levels of fatty acid binding protein 3 (FABP3), CCL2/monocyte chemotactic protein-1 34 
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(MCP-1), CXCL8/interleukin-8, and vascular endothelial growth factor (VEGF) were 1.5- to 10- 1 
times higher in CSF than in plasma. These observations indicate that a majority of the 2 
communicome factors, many known classically for their role in peripheral immune function, 3 
developmental processes, or systemic diseases, may have a function in the CNS as well.  4 
 5 
CSF communication factors can model CSF Aβ  and tau and hence discriminate between AD 6 
and NDC. 7 
Consistent with published reports (9, 11, 31) CSF levels of Aβ42, t-tau, p-tau181 alone or in 8 
combination were strong classifiers of AD in our data set (area under the curve (AUC) 0.75-0.90 9 
for various models; Table II). If levels of communication factors are indeed associated with the 10 
disease process (discussed in (6)) they should be able to model the pathological changes 11 
characteristic of AD (Fig 1). We thus modeled levels of CSF Aβ42, t-tau, p-tau181, or ratios Aβ42/t- 12 
tau or Aβ42/p-tau181 with all measurements of communication factors in CSF (73 detectable 13 
factors) using the linear regression-modeling tool Elastic net (E-net, (27)). We adjusted for sex and 14 
AD risk factors age and APOE4 status by including them as variables in the analysis. In E-net 15 
models C1–C5 a total of 12 CSF proteins were selected to be associated with the 5 pathological 16 
markers of AD. Interestingly, FABP3 and creatine kinase-muscle/brain (CK-MB), showed a 17 
consistently strong association in all models involving tau; (indicated by shades of green in Table I) 18 
endothelin-1, and interleukin-13 (IL-13) were also required to model p-tau181. IL-7 was the only 19 
factor selected to model Aβ42 but with a regression coefficient of nearly zero, implying that its 20 
influence on the response variable in the regression model is small.  21 
The communication factors selected in E-net Models C2 and C5 (the latter in conjunction 22 
with APOE4 status) were capable of independently classifying AD and NDC similar to or slightly 23 
better than p-tau181 or Aβ42/p-tau181 levels measured in these patients (Fig 2A,B and Table II). 24 
This validates the chosen communication proteins and suggests that they are biologically related 25 
to the abundance of p-tau181 and Aβ42 in CSF, the pathological hallmarks of AD.  26 
Consistent with the E-net analysis, we observed in the connectivity network diagram of the 27 
overall 12 selected CSF communication factors strong, positive Spearman rank correlations (RS) 28 
between t-tau or p-tau181 and a number of communication factors in healthy individuals but Aβ42 29 
was only weakly integrated into this network (Fig 2C). Other factors including CXCL8, FABP3, 30 
matrix metalloproteinase 3 (MMP-3), and stem cell factor (SCF) show strong correlations with each 31 
other in this network (RS ≥ 0.8). While some of these relationships are maintained in AD (FABP3, 32 
MMP-3, SCF), the strong correlations with tau are missing; instead, negative relationships between 33 
tau, CK-MB, and TNF-β appear, and C-reactive protein (CRP) becomes a network hub with 34 
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several positive interactions (Fig 2D). This change in connectivity between pathological and 1 
communicome factors in AD versus NDC is reflected by differences in the interaction scores. 2 
 3 
Plasma communication factors can model CSF tau and Aβ   and hence discriminate between 4 
AD and NDC. 5 
We next asked whether blood-derived proteins have a relationship to CSF pathological markers of 6 
AD and may thus be related to the disease itself (Fig 1). We again used E-net to model Aβ42, t- 7 
tau, p-tau181, or ratios Aβ42/t-tau or Aβ42/ p-tau181 but this time based on values for 74 detectable 8 
plasma communication proteins (Table S2) in a training set of 52 AD patients and 79 NDC (Table 9 
S1), and we adjusted for sex, age and APOE4 status. A total of 22 plasma communication factors 10 
were selected to best model pathological CSF markers in E-net Models P6–P10 (Table I). Notably, 11 
CK-MB and tumor necrosis factor-β (TNF-β) overlapped with proteins selected in the CSF models. 12 
Among the 22 proteins, macrophage-colony stimulating factor (MCSF) showed the strongest and 13 
most consistent association with all 5 pathological markers in CSF although APOE4 status and 14 
age were key drivers in two of these models (P8, P9). Other prominent factors were selected in 15 
four models (CK-MB and granulocyte-colony stimulating factor (G-CSF)) or in three models (TNF- 16 
RII, IL-3 and PAI-1) (indicated by shades of orange in Table I). 17 
To assess the potential diagnostic utility of the selected plasma proteins we calculated 18 
ROC curves for the training set. Several models outperformed the pathological CSF markers in 19 
classifying NDC and AD, and this effect was not simply explained by APOE4 status and age 20 
(Table II and Fig 3A,C). Moreover, plasma communication factors in combination with APOE4 21 
status and age were as effective in classifying AD as CSF measurements of Aβ42/tau and Aβ42/p- 22 
tau181 (Table II). We validated the results of these models in an independent test set with 65 23 
subjects (Table S1), producing a classification (AUC 0.74-0.77), which was clearly stronger than 24 
with APOE4 status and age alone (AUC 0.63, Fig 3B,D). 25 
Consistent with the E-net analysis, connectivity network diagrams illustrated a considerable 26 
complexity of relationships between all 22 plasma communication factors selected by E-net models 27 
P6–P10 and tau and Aβ in NDC (Fig 4A). Interestingly, this network becomes seemingly more 28 
complex in AD subjects where immune and inflammatory factors become important network hubs 29 
(Fig 4B). For example, β2-microglobulin shows strong correlations with inflammatory factors TIMP- 30 
1, PAI-1 and members of the TNF superfamily (CD40L, TNF RII, and TNF-β) in the AD network. 31 
 32 
Correlations and connectivity between communication factors in CSF and plasma are 33 
altered in AD. 34 
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To assess whether levels of a given protein factor in the CSF are related to its levels in plasma we 1 
compared CSF and plasma concentrations in 43 subjects using Spearman rank correlation. In 2 
healthy individuals, levels of 10 out of the 60 proteins detectable in CSF and plasma (Table S2) 3 
correlated considerably between the two fluids (Rs ≥ 0.5; Fig 5A). Strikingly, 6 of these 10 4 
correlations were much weaker in AD (FABP3, IL-10, TIMP-1, CCL4 (macrophage inflammatory 5 
protein-1β, MIP-1β), myoglobin, and TSH. Conversely, levels of intercellular adhesion molecule-1 6 
(ICAM-1) and CCL5 did not correlate between CSF and plasma in NDCs but correlated highly in 7 
AD patients (Fig 5A and S1). Similarly, it becomes apparent that the connectivity network of 8 
factors selected in models C1–5 and P6–10  (Fig 5B,C) are overall very different in AD and NDC, 9 
and this is supported by the change in interaction scores for each factor. Many of the factors 10 
appearing as well-connected network hubs in healthy individuals (e.g. insulin, α-fetoprotein, 11 
FABP3, or SCF) have very low connectivity in AD patients. In turn, MCSF and CRP have high 12 
positive correlations in AD but negative or fewer correlations in NDC. Together, these analyses 13 
across the BBB support the notion that the disease process in AD is accompanied by changes in 14 
secreted signaling proteins in CSF and plasma. 15 
 16 
 17 
DISCUSSION 18 
The study of genetic forms of AD has greatly advanced our knowledge about disease processes 19 
linked to the disease but the cause of sporadic forms of AD affecting >95% of all patients is 20 
unknown. One reason may be that studying this disease is typically limited to imaging or 21 
psychometric testing of patients. Also, existing in vitro or transgenic animal models based on 22 
genetic forms of AD provide limited unbiased information on molecular or cellular networks 23 
involved in the pathogenesis of sporadic AD. Here we analyzed AD in a more continuous and 24 
complex fashion based on the hypothesis that the systemic network of the extracellular signaling 25 
proteome is linked with the pathological traits in AD. To test this hypothesis we modeled known 26 
and accepted pathological indicators of the disease (Aβ42, t-tau, p-tau181, or ratios Aβ42/t-tau or 27 
Aβ42/p-tau181) (4, 5) with other CSF or plasma proteins (Fig 1 and Table S2) using the penalized 28 
linear regression method E-net (27). We also correlated levels of proteins measured in CSF and 29 
plasma with each other and analyzed how the connectivity or “network” of correlations between 30 
these factors changes with disease (Fig 1). The current study attempts therefore to provide 31 
methods for discovery of potentially diagnostic or biologically relevant proteins in AD.  32 
 We discovered several small groups of proteins in CSF which could be used to model or 33 
predict levels of pathological markers and classify AD and non-demented controls with similar or 34 
  11/26 
better diagnostic utility than the CSF pathological markers themselves (Fig 2A,B and Table II). 1 
These proteins alone or in combination may therefore be associated with the disease process 2 
either in a direct or indirect way [see also discussion on fluid biomarkers in relation to AD 3 
pathology in (6)], and future experimental studies will need to test this. Consistent with their ability 4 
to model CSF tau and Aβ, several of the selected CSF communicome proteins correlate with these 5 
markers and it is striking that most correlations are prominently changed in AD patients (Fig 2C,D). 6 
This is particularly obvious for correlations between FABP3 or SCF, and pathological markers. 7 
FABP3, which shows many strong correlations with other proteins and functions as a network hub, 8 
is a cytosolic protein involved in cellular fatty acid uptake, transport, and metabolism (32). It is 9 
highly expressed in the adult human brain (33) and has previously been suggested to be a 10 
peripheral marker for mild traumatic brain injury and stroke (33-35). In support of a possible 11 
change in the half-life of FABP3 in brain and the systemic environment in disease, we observed a 12 
moderate positive correlation between CSF and blood FABP3 levels in NDC but a negative 13 
correlation in AD patients (Fig 5A and S1). FABP3 was also independently identified as a possible 14 
predictor of AD in a recent ELISA study (36) and two studies of CSF communicome proteins using 15 
the same platform that was used in our study (15, 37). Other proteins overlapping between our 16 
analysis and the latter two studies include IL-7, SCF, and CCL11/eotaxin (with Hu et al. identifying 17 
its close relative Eotaxin-3/CCL26).  18 
 Using levels of plasma communicome proteins to model AD pathological markers we 19 
identified between 4 and 15 proteins (out of 74 detectable proteins; Table S2) for the various 20 
models P6-P10. The selected proteins were slightly weaker in their diagnostic utility than the ones 21 
selected in CSF models C2, C4, and C5 but outperformed models C1 and C3 (Table II). All plasma 22 
models required age and APOE4 status as parameters to achieve sufficient classification accuracy 23 
(Fig 3 and Table II). Further validation of the models in an independent test set resulted in reduced 24 
AUC values but a clear improvement over the classification accuracy with APOE4 status and age. 25 
Since each of the 5 plasma models was developed independently with the E-net tool, it is 26 
reassuring that several proteins were selected in 3, 4 or even all models (shades of orange in 27 
Table 1). Of these, MCSF and G-CSF may be particularly relevant in AD, as they are reduced in 28 
AD plasma (17) and systemic administration of either MCSF (38) or G-CSF (39) ameliorated 29 
memory deficits in mouse models of the disease. Furthermore, MCSF functions as a network hub 30 
and shows strong positive correlations with FABP3, SCF, and MMP-3 in the CSF-plasma 31 
connectivity diagram in AD patients but not in NDC (Fig 5B,C).  32 
The comparison of individual correlations of communicome proteins between CSF and 33 
plasma in AD and NDC (Fig 5A) resulted in an additional set of proteins which overlapped in part 34 
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with those identified in models C1–C5 (FABP3, CRP) and P6–P10 (CCL2) as well as proteins 1 
reported in the literature as having a role in AD (CCL5, ICAM-1, leptin). Notably, many of these 2 
correlations are different in AD compared with NDC. Whether the correlations between CSF and 3 
plasma are the result of exchange between the compartments or co-regulation of these proteins 4 
and why the correlations change with disease needs to be explored mechanistically. It is 5 
reassuring that out of a 18 protein signature we previously described to classify AD or model 6 
progression (17) all 6 proteins that were detectable on the two distinct platforms were selected in 7 
at least one model here (CCL5, CXCL8, GCSF, ICAM-1, IL-3, MCSF). Likewise, in a recent study 8 
that used the multiplex sandwich immunoassay platform to measure 108 serum proteins (including 9 
the ones measured here) (16), several predictors of AD overlapped with the ones identified here 10 
(e.g. CK-MB, G-CSF).  11 
In the future, the analytical methods described here could be improved by increasing the 12 
number of communication factors measured in the plasma or CSF and modeling not only 13 
pathological CSF markers but clinical or imaging parameters as well. This could strengthen the 14 
value of biological information obtained with this approach. At the same time, this analytical 15 
method could go beyond the communicome as we know it today by combining it with the analysis 16 
of cellular networks (40) or other "–omic" approaches (41) to discover associations with disease 17 
patterns in tissue. Naturally, these methods are not limited to AD but could be used for other 18 
diseases where direct access to the diseased organ is difficult. Ultimately, the proteins and 19 
biological pathways identified by these analytical approaches need to be validated using 20 
appropriate disease models and ultimately, human studies. 21 
In summary, we measured with a targeted proteomic multiplex assay soluble proteins 22 
involved in intercellular communication in CSF and plasma of AD patients and cognitively normal 23 
elderly controls. We identified with a high-dimensional linear regression method those proteins that 24 
are associated with CSF levels of Aβ and tau, which are pathologically changed in AD, and show 25 
AD-related changes in correlations and connectivity networks between these identified proteins 26 
within CSF, plasma, or across the BBB. We propose that these network-based analytical 27 
approaches can help identify proteins or signaling pathways involved in AD or other chronic 28 
neurodegenerative disorders with higher confidence than traditional two-class, disease/control 29 
modeling approaches. Future studies need to replicate our findings in large multi-center cohorts 30 
and test the various proteins for the biological role in AD. 31 
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FIGURE LEGENDS 
 
Fig 1. Modeling of pathological markers in CSF and classification of AD based on 
communication factors in CSF and plasma. Accumulation of plaques and tangles in the AD 
brain is associated with decreased levels of Aβ and increased levels of tau in CSF, respectively 
(green dashed double arrow). Relative levels of these proteins alone or their ratios can be used to 
classify AD and NDC (green solid arrow). In Elastic net (E-net) regression models C1–C5 soluble 
communication factors in CSF (CSF communicome; see text for details) are used to model tau and 
Aβ levels or their ratios (dashed purple double arrow) and subsequently to classify AD and NDC 
(solid purple line). In E-net models P6–P10 soluble communication factors in plasma (plasma 
communicome) derived from the training set are used to model tau and Aβ levels or their ratios 
(dashed red double arrow) and subsequently to classify AD and NDC (solid red line). These 
variables were validated by classifying AD and NDC in an independent test set. In a separate 
analysis correlations are studied between CSF communicome proteins and corresponding plasma 
communicome proteins in AD patients and NDCs (dashed blue double arrow). 
 
 
Fig 2. Pathology associated CSF communicome models can classify AD and NDC and the 
connectivity network of the proteins in these models is altered in AD patients. (A, B) CSF 
pathological markers or CSF Elastic net (E-net) models C2 and C5 were used to calculate ROC 
curves. The color-coding is based on Fig 1 and the numbers indicate the AUC values and 95% C.I. 
(listed also in Table III). (A) CSF samples from AD patients and NDC were classified based on 
levels of CSF p-tau181 (solid green line) or levels of CSF communicome proteins (FABP3, CCL11, 
endothelin-1, CK-MB, IL-13, CXCL8) and APOE4 status selected in model C2 (dashed purple line). 
(B) CSF samples from AD patients and NDC were classified based on levels of CSF Aβ42/p-tau181 
(solid green line) or levels of CSF communicome proteins (FABP3, IL-13, SCF, CK-MB, α-
fetoprotein, endothelin-1, CRP) and APOE4 status selected in model C5 (dashed purple line). (C, 
D) Network diagrams illustrating connectivity between CSF pathological markers and CSF 
communication factors selected in models C1–C5. The connectivity between two proteins is 
expressed as Spearman rank correlation coefficient RS calculated from all measurements for these 
two proteins in CSF samples of non-demented controls (C) or AD patients (D), respectively. The 
correlations are visualized in a network with different strokes and colors depending on strength and 
type of connectivity between proteins. Red strokes RS ≥ 0.4, blue strokes RS ≤ –0.4. In 
parentheses next to the name of the analyte is the interaction score, which is the sum of the 
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squared values of all RS between all analytes in the connectivity diagram. Note the considerable 
change of the interaction scores between communication factors in AD patients (D) compared with 
NDC (C). 
 
 
Fig 3. Pathology associated plasma communicome models that efficiently classify AD and 
NDC are validated in an independent test set. ROC curves for the plasma training and a test set 
were calculated with CSF pathological markers (solid green lines), AD risk factors APOE4 status 
and age (solid black lines), or plasma Elastic net (E-net) models P2 and P5 (dashed red lines), 
respectively. The color-coding is based on Fig 1 and the numbers indicate the AUC values and 
95% C.I. (listed also in Table III). (A) AD patients and NDC in the training set were classified 
based on levels of CSF p-tau181 or the variables selected to be associated with p-tau181 in e-net 
model P2: plasma communicome proteins (MCSF, CD40L, G-CSF, adiponectin, CCL2, CK-MB, 
TNF-β, β2-microglobulin, TNF RII, IL-4, IL-3, IL-18, PAI-1, Apo CIII, TBG), APOE4 status, and age. 
(B) The variables selected in the training set E-net model P2 are validated in an independent test 
set of AD and NDC and compared to the ROC curves that were calculated based either on levels 
of CSF p-tau181 or APOE4 status and age of 53 of the 65 subjects in the test set; measurements of 
Aβ42 and tau were not done for 6 NDC and 6 AD in the test set. (C) AD patients and NDC in the 
training set were classified based on levels of CSF Aβ42/p-tau181 or the variables selected to be 
associated with p-tau181 in E-net model P10: plasma communicome proteins (MCSF, G-CSF, GH, 
TPO), APOE4 status, and age. (D) The variables selected in the training set E-net model P10 are 
validated in an independent test set of AD and NDC and compared to the ROC curves that were 
calculated based either on levels of CSF Aβ42/p-tau181 or APOE4 status and age of the subjects in 
the test set. See connectivity network in Fig 4 for illustration of the changes in interactions between 
communication factors in AD patients compared with controls.   
 
 
Fig 4. Plasma predictors of pathological markers point to changes in the communicome 
network in plasma of AD patients. (A, B) Connectivity diagrams of pathological markers in CSF 
and communication factors in plasma, which were chosen in Elastic net regression models for 
these markers. The relationship between two proteins is expressed as Spearman rank correlation 
coefficient RS calculated from all measurements for these two proteins in non-demented controls 
(A) or AD patients (B), respectively. The correlations are visualized in a network with different 
strokes and colors depending on strength and type of a relationship between proteins. Red strokes 
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RS ≥ 0.4, blue strokes RS ≤ –0.4. In parentheses next to the name of the analyte is the interaction 
score, which is the sum of the squared values of all RS between all analytes in the connectivity 
diagram. Note the considerable difference in connectivity between communication factors in AD 
patients compared with NDC. 
 
 
Fig 5. Correlations and connectivity between communication factors in CSF and plasma are 
different in AD patients compared with NDC. (A) Spearman rank correlations (correlation 
coefficient RS) between CSF and plasma in non-demented controls (green bars) and AD patients 
(blue bars). Proteins with RS ≥ 0.5 in at least one group are shown. RS ≤ –0.5 were not observed. 
Note that levels of CCL5 and ICAM-1 correlate much stronger in AD than in NDC across the BBB 
and that ApoH and CCL2 reach RS = 0.5 in AD but not in NDC. (B, C) Connectivity diagrams 
illustrating correlations between CSF communication factors selected in models C1–C5 and 
plasma communication factors selected in models P6–P10. In parentheses are the interaction 
scores. See legend to Fig 2 for more details on calculations. Note the considerable lack and 
difference in connectivity between communication factors in AD patients (C) compared with NDC 
(B). See also Fig S1. BBB, blood-brain barrier. 
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 Table I. List of variables selected in the Elastic net models.  
Variables selected in the models for CSF a 
Model C1: t-tau Model C2: p-tau181 Model C3: Aβ42 Model C4: Aβ42/t-tau Model C5: Aβ42/ p-tau181 
FABP3 (0.34) FABP3 (0.41) IL-7 (0) FABP3 (-0.17) APOE (-0.28) 
CK-MB (-0.10) CCL11 (-0.21)  APOE (-0.15) FABP3 (-0.10) 
 APOE (0.21)  SCF (-0.11) IL-13 (-0.08) 
 Endothelin-1 (0.20)  Endothelin-1 (-0.07) SCF (-0.08) 
 CK-MB (-0.20)  TNF-β (-0.03) CK-MB (-0.05) 
 IL-13 (0.19)  CK-MB (0.03) α-Fetoprotein (-0.03) 
 MMP-3 (0.18)   Endothelin-1 (-0.03) 
 CXCL8 (-0.17)   CRP (0.01) 
 +18 more c    
     
Variables selected in the models for plasma b 
Model P6: t-tau Model P7: p-tau181 Model P8: Aβ42 Model P9: Aβ42/t-tau Model P10: Aβ42/ p-tau181 
TNF RII (0.08) MCSF (-0.07) APOE (-0.31) APOE (-0.32) APOE (-0.21) 
Age (0.06) CD40L (-0.04) Age (-0.24) Age (-0.28) MCSF (0.15) 
MCSF (-0.06) APOE (0.04) MCSF (0.15) MCSF (0.17) Age (-0.12) 
TF (0.06) G-CSF (-0.04) IL-18 (0.02) IL-12 p70 (0.07) G-CSF (0.12) 
IL-3 (0.04) Adiponectin (0.04) IL-12 p70 (0.02) CK-MB (0.04) GH (0.03) 
APOE (0.04) CCL2 (-0.02) IgA (0.01) IL-4 (-0.03) TPO (0.01) 
ApoCIII (-0.02) CK-MB (-0.02) CK-MB (<0.01) TIMP-1 (0.02)  
Adiponectin (0.02) TNF-β (0.01)  G-CSF (0.02)  
EN-RAGE (0.02) Age (0.01)  β2-Microglobulin (-0.02)  
G-CSF (-0.02) β2-Microglobulin (0.01)  TNF RII (-0.01)  
CK-MB (-0.01) TNF RII (0.01)  EN-RAGE (-0.01)  
Insulin (-0.01) IL-4 (0.01)  TF (-0.01)  
CD40L (-0.01) IL-3 (0.01)  PAI-1 (0.01)  
PAI-1 (-0.01) IL-18  IL-3  
 PAI-1    
 Apo CIII    
 TBG    
 
a  Based on the CSF set with 43 subjects, AD n = 25, NDC n = 18 subjects.  
b  Based on the training set with 131 subjects, AD n= 52, NDC n = 79 subjects. 
c In model C2 the E-net chose 26 predictors for modeling p-tau181p with CSF proteins and subjects' characteristics. To avoid overfitting 
for this model we limited the number of selected variables to 8. The additional 18 variables in order of how they were selected by the 
E-net here in an extended list: CRP, age, VEGF, SCF, CA19-9, IL-10, IL-5, C3, haptoglobin, TBG, calcitonin, GST, CCL2, α-
fetoprotein, PAPP-A, ApoA1, CCL3, IgM. 
d Note that for Aβ42 only one variable was selected with a very small estimated regression coefficient. 
All values were standardized and penalized linear regression models were calculated with the E-net method. Response variables: t-tau, 
p-tau181, Aβ42, or the ratios of Aβ42/t-tau, or Aβ42/p-tau181. Explanatory variables: CSF or plasma protein levels together with sex and 
risk factors for AD APOE genotype and age. For each response a separate model was calculated (Model C1-5 in CSF, P6-8 in plasma) 
and variables that fitted best into the corresponding model are listed in order of decreasing absolute size of the estimated regression 
coefficient (RC, indicated in parentheses). Since all variables had been standardized, the RC serves as a measure of the strength for the 
association between an explanatory variable and its corresponding response variable: the larger RC in absolute value, the higher the 
association to the response. A RC close to 0 points to a low degree of association between the corresponding variable and the 
response. For protein nomenclature see Table S2. 
Suggested location in the text: Results, after second subtitle 
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Table II. Classification of AD and non-demented controls. 
 CSF sample set (n = 43) 
Established 
biomarker model 
AUC calculated based on 
established biomarkers in CSF a E-net model 
AUC calculated based on CSF 
communicome, age, and APOE4 status b 
t-tau 0.86 (0.71-0.94) C1 0.75 (0.56-0.88) 
p-tau181 0.90 (0.74-0.97) C2 0.88 (0.70-0.96) 
Aβ1-42 0.75 (0.58-0.87) C3 n.a. 
Aβ1-42/t-tau 0.84 (0.69-0.93) C4 0.91 (0.77-0.97) 
Aβ1-42/p-tau181 0.86 (0.70-0.94) C5 0.93 (0.78-0.98) 
    
 Training set (n = 131) 
Established 
biomarker model 
AUC calculated based on 
established biomarkers in CSF a E-net model 
AUC calculated based on plasma 
communicome, age, and APOE4 status b 
t-tau 0.80 (0.71-0.87) P6 0.86 (0.79-0.92) 
p-tau181 0.82 (0.73-0.89) P7 0.86 (0.78-0.92) 
Aβ1-42 0.81 (0.72-0.87) P8 0.85 (0.76-0.90) 
Aβ1-42/t-tau 0.85 (0.78-0.91) P9 0.86 (0.78-0.92) 
Aβ1-42/p-tau181 0.84 (0.76-0.90) P10 0.84 (0.76-0.90) 
    
 Test set (n = 65) 
Established 
biomarker model 
AUC calculated based on 
established biomarkers in CSF c 
Validation 
of variables 
selected in 
E-net model 
AUC calculated based on plasma 
communicome, age, and APOE4 status 
selected in the training set d 
t-tau 0.80 (0.630-0.907) P6 0.77 (0.63-0.87) 
p-tau181 0.81 (0.648-0.909) P7 0.76 (0.61-0.86) 
Aβ1-42 0.84 (0.704-0.925) P8 0.75 (0.60-0.85) 
Aβ1-42/t-tau 0.86 (0.715-0.938) P9 0.77 (0.63-0.87) 
Aβ1-42/p-tau181 0.86 (0.725-0.934) P10 0.74 (0.60-0.85) 
 
a AUC calculated based on the levels of established pathological CSF biomarkers t-tau, p-tau181, Aβ1-42 and their ratios in subjects 
used for CSF or plasma models, respectively. 
b AUC (in bold) calculated based on communicome, age and APOE4 status  and their corresponding regression coefficients as 
selected in Elastic net (E-net) models C1-5 (CSF) and P6-10 (plasma) in subjects used for CSF or plasma models, respectively. Note 
that for Aβ1-42 only IL-7 with a regression coefficient close to 0 was selected in the E-net model C3. Thus, no ROC/AUC could be 
calculated (n.a., not applicable). 
c These AUC results are based on 53 subjects because 6 controls and 6 AD patients had no measurement of Aβ and tau in CSF.  
d Variables selected by the E-net models P6-10 in the training set were validated in an independent test set and AUC was calculated for 
all 65 subjects (italicized and bold). 
 
Compare AUC calculated using variables selected in elastic net models (Table I) with AUC calculated using established markers for 
pathology. See also ROC curves in Figures 2 and 3. 
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Fig 1. Modeling of pathological markers in CSF and classification of AD based on 
communication factors in CSF and plasma.  
Suggested location in the text: Results, before second subtitle 
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Fig 2. Pathology associated CSF communicome models can classify AD and NDC and the 
connectivity network of the proteins in these models is altered in AD patients.  
Suggested location in the text: Results, before third subtitle 
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Fig 3. Pathology associated plasma communicome models that efficiently classify AD and 
NDC are validated in an independent test set.  
Suggested location in the text: Results, before fourth subtitle 
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Fig 4. Plasma predictors of pathological markers point to changes in the communicome 
network in plasma of AD patients.  
Suggested location in the text: Results, right after Figure 3 
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Fig 5. Correlations and connectivity between communication factors in CSF and plasma are 
different in AD patients compared with NDC.  
Suggested location in the text: Results, before discussion 
 
 
 
 
 
